Engineered immune cells take aim at Hard-to-Treat blood cancer
NCT ID NCT07333430
First seen Jan 12, 2026 · Last updated Jun 22, 2026 · Updated 22 times
Summary
This early-stage trial is testing a new treatment called HBI0101 CAR-T for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The study aims to find a safe dose and see if the treatment can shrink tumors, enrolling about 60 adults.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hadassah MO, Jerusalem, 9574869
RECRUITINGJerusalem, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HBI0101 CAR-T cells (a patient's own immune cells modified to target cancer)
What this could lead to
If successful, this could point toward a new treatment option for multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1) trial with only 60 people, so it may not work or could have serious side effects. The treatment is still experimental.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.